Preclinical research has indicated that increased tumor expression of RRM1 is the major determinant of resistance to gemcitabine [6], and two cell line studies have demonstrated an association between gemcitabine resistance and gene amplification of RRM1[7,8]. The gene discussed is RRM1; the disease is neoplasm.